#retinitis-pigmentosa

[ follow ]
#gene-therapy #biotech-investment #clinical-development #rare-disease #vision-loss #blindness #identity #theatre
Medicine
from24/7 Wall St.
1 week ago

Oppenheimer Starts Ocugen (OCGN) at Outperform on Gene Therapy Pipeline

Oppenheimer initiated Outperform coverage of Ocugen with a $10 price target, betting on OCU400's potential 2027 approval as a gene-agnostic treatment for retinitis pigmentosa affecting a broad patient population.
Medicine
fromwww.theguardian.com
3 months ago

My cultural awakening: The Lehman Trilogy helped me to live with my sight loss

Retinitis pigmentosa caused progressive tunnel vision, triggering identity loss, social withdrawal, and later emotional reconnection through a theatre experience that restored a sense of seeing.
[ Load more ]